Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

CDKN2A overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

CDKN2A overexpression	Estrogen Receptor Positive Breast Cancer	CDKN2A overexpression	Estrogen Receptor Positive Breast Cancer	CDK6 inhibitor Resistant: D – Preclinical Nat Commun - 3 weeks (New D) CDK6 inhibitor Resistant : D Nat Commun - 3wk	CDK6 inhibitor Resistant: D – Preclinical Nat Commun - 3 weeks CDK6 inhibitor Resistant : D Nat Commun - 3 weeks - (New D)
CDKN2A overexpression	Estrogen Receptor Positive Breast Cancer	CDKN2A overexpression	Estrogen Receptor Positive Breast Cancer	CDK4 inhibitor Resistant: D – Preclinical Nat Commun - 3 weeks (New D) CDK4 inhibitor Resistant : D Nat Commun - 3wk	CDK4 inhibitor Resistant: D – Preclinical Nat Commun - 3 weeks CDK4 inhibitor Resistant : D Nat Commun - 3 weeks - (New D)
CDKN2A overexpression	Soft Tissue Sarcoma	CDKN2A overexpression	Soft Tissue Sarcoma	olaparib + trabectedin Sensitive: C3 – Early Trials olaparib + trabectedin Sensitive : C3	olaparib + trabectedin Sensitive: C3 – Early Trials olaparib + trabectedin Sensitive : C3
CDKN2A overexpression	Ovarian Cancer	CDKN2A overexpression	Ovarian Cancer	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D
CDKN2A overexpression	Mantle Cell Lymphoma	CDKN2A overexpression	Mantle Cell Lymphoma	venetoclax Sensitive: D – Preclinical venetoclax Sensitive : D	venetoclax Sensitive: D – Preclinical venetoclax Sensitive : D